Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease

Key facts

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Intervention

Rovadicitinib(drug)

Enrollment

182 target

Eligibility

18-70 years · All sexes

Timeline

2024 – 2030

Study locations (30)

• The First Affiliated Hospital of USTC Anhui Provincial Hospital, Hefei, Anhui, China
• Peking University First Hospital, Beijing, Beijing Municipality, China
• Peking University People's Hospital, Beijing, Beijing Municipality, China
• The Southwest Hospital of AMU, Chongqing, Chongqing Municipality, China
• Fujian Medical University Union Hospital, Fuzhou, Fujian, China
• The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
• The First Hospital of Lanzhou University, Lanzhou, Gansu, China
• The 904 Hospital of the Joint Service Support Force of the People's Liberation Army of China, Lanzhou, Gansu, China
• Guangzhou First People's Hospital The First People's Hospital Affiliated to Guangzhou Medical University, Guangzhou, Guangdong, China
• Nanfang Hospital, Guangzhou, Guangdong, China
• The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
• The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China
• The Second Hospital of Hebei Medical Hospital, Shijiazhuang, Hebei, China
• Henan Provincial People's Hospital, Zhengzhou, Henan, China
• The Third People's Hospital of Zhengzhou, Zhengzhou, Henan, China
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Graft versus host disease

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07025538
  Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation
  City of Hope Medical Center
• RECRUITINGPHASE1NCT06996119
  Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
  City of Hope Medical Center
• RECRUITINGPHASE2NCT07566377
  Cord Blood Transplantation in Children and Young Adults With Blood Cancer
  Memorial Sloan Kettering Cancer Center
• RECRUITINGPHASE2NCT06926595
  Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention
  Milton S. Hershey Medical Center
• RECRUITINGEARLY PHASE1NCT07253259
  A Clinical Study Evaluating the Safety and Efficacy of GT729 Universal Cell Injection in the Treatment of Refractory or Relapsed Chronic Graft-versus-host Disease (cGVHD)
  Grit Biotechnology
• RECRUITINGNANCT07166848
  Electrostimulation Study for Ocular Graft vs. Host Disease
  Zhonghui K. Luo, MD, PhD
• RECRUITINGPHASE2NCT07246031
  BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell Transplantation
  BioPhoenix Co., Ltd.
• RECRUITINGNCT07305090
  Development of a Multi-biomarker Panel for Prognostic Stratification and Treatment Response Prediction in Acute Graft Versus Host Disease of the Gut
  IRCCS Azienda Ospedaliero-Universitaria di Bologna

See all trials for Graft versus host disease →